Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,200.05 24.08 0.76%
FTSE 100 6,710.41 35.67 0.53%
DAX 9,613.98 69.79 0.73%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

ARIAD to Present at the 31st Annual J.P. Morgan Healthcare Conference



  ARIAD to Present at the 31st Annual J.P. Morgan Healthcare Conference

JPMorgan Healthcare Conference 2013

Business Wire

CAMBRIDGE, Mass. -- January 2, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the 31st Annual J.P. Morgan Healthcare Conference being held in San
Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will
provide an overview of the Company’s business on Monday, January 7 at 4:30
p.m. (PT).

The ARIAD presentation at the J.P. Morgan Healthcare Conference will be
webcast live and can be accessed by visiting the investor relations section of
the Company's website at http://www.ariad.com/investor. A replay of the
presentation will also be available and archived on the site for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the
lives of cancer patients. ARIAD’s first medicine, Iclusig™, is approved in the
U.S. for the treatment of adult patients with chronic, accelerated or blast
phase chronic myeloid leukemia that is resistant or intolerant to prior
tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive
acute lymphoblastic leukemia that is resistant or intolerant to prior TKI
therapy. Additional clinical trials of Iclusig in other cancers are ongoing.
ARIAD is also studying AP26113, another molecularly targeted medicine, in
certain forms of lung cancer. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement